Medicamen Organics Limited — Important, 27-01-2026: Updates

Medicamen Organics seeks shareholder approval to reallocate ₹1.62 Cr (15.41% of IPO funds) from product registration to working capital for new projects, aiming to boost efficiency and growth. The company also seeks approval for director remuneration and the re-appointment of Ashutosh Gupta (son of CMD) as Whole-Time Director.